AI Article Synopsis

  • - The CELSUS study in Greece evaluated the effectiveness of Calcipotriol/Betamethasone (Cal/BD) aerosol foam for psoriasis treatment and found it led to significant patient satisfaction and treatment success across various disease severities.
  • - Out of 400 patients, those naïve to treatment had better success rates (72.6% for mild, 56.5% for moderate, and 66.7% for severe) compared to treatment-experienced patients (60.7%, 42.2%, and 25% respectively) after 4 weeks.
  • - Overall, both treatment-naïve and treatment-experienced patients showed notable reductions in psoriasis symptoms, with the most significant improvements seen

Article Abstract

Fixed combination calcipotriol/betamethasone (Cal/BD) aerosol foam has been shown to be effective in psoriasis treatment in clinical trials, but real-world evidence is currently sparse. The real-world CELSUS study in Greece found that Cal/BD aerosol foam treatment was effective and associated with satisfaction in psoriasis patients. Patients from the CELSUS study (N = 400) were stratified by baseline disease severity according to physician's global assessment (PGA) score (mild vs. moderate vs. severe) and by previous psoriasis treatment (naïve vs. treatment-experienced). Proportions of patients achieving treatment success (clear/almost clear [PGA 0/1]) after 4 weeks' treatment with Cal/BD aerosol foam were reported for each subgroup. Psoriasis area and severity index (PASI) and patient-reported itch, itch-related sleep loss, scaling, dry skin, and erythema numerical rating scores were reported by subgroup. At baseline, 216 (54%) patients were systemic-or-topical psoriasis treatment-naïve and 184 (46%) were treatment experienced. By disease severity, there were 135 versus 89 patients with mild, 69 versus 83 with moderate and 12 versus 12 with severe disease in the treatment-naïve versus treatment-experienced groups, respectively. In the treatment-naïve group, treatment success was achieved by 72.6%, 56.5%, and 66.7% of patients with mild, moderate, and severe disease, respectively, while the proportions in the treatment-experienced group were 60.7%, 42.2%, and 25%, respectively. Reduction from baseline in psoriasis symptoms was observed in all patient groups. The greatest reductions were observed in treatment-naïve patients with severe disease. Clinically relevant benefits were observed with Cal/BD aerosol foam in psoriasis patients, regardless of prior treatment-experience and disease severity at baseline.

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.15484DOI Listing

Publication Analysis

Top Keywords

aerosol foam
20
disease severity
16
cal/bd aerosol
16
psoriasis treatment
12
severe disease
12
patients
9
psoriasis
9
baseline disease
8
treatment
8
celsus study
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!